セッション詳細
[WS(P)22]New molecular and cellular mechanisms in cancer immunology
2024年12月4日(水) 16:40 〜 17:25
Poster 7
[WS22-01-O/P]Satb1 maintains the functionality of regulatory and cytotoxic T cells during tumor responses
○Wooseok Seo1,2, Chengcheng Zou2, Kanako Shimizu2, Ruka Setoguchi3, Kiyokazu Kakugawa2, Krutula Nair2, Haruhiko Koseki2, Terumi Kohwi-Shigematsu4, Shohei Hori3, Shin-ichiro Fujii2, Hiroyoshi Nishikawa1, Ichiro Taniuchi2 (1.Nagoya University / Dep. of Immunology, 2.RIKEN, 3.University of Tokyo, 4.University of California)
[WS22-02-P]Naturally arising memory-phenotype CD4+ T lymphocytes differentiate into Th1, Th17, and Treg cells to contribute to tumor immunity while inhibiting graft-versus-host disease
○Feng Gao, Ziying Yang, Jing Li, Akihisa Kawajiri, Kosuke Sato, Shunichi Tayama, Naoto Ishii, Takeshi Kawabe (Department of Microbiology and Immunology, Tohoku University, Graduate School of Medicine.)
[WS22-03-P]Type-I IFN signaling in the gut lymphoid tissue regulates the polyamine homeostasis in the peripheral CD8+ T cells
○Kana Yamasaki1, Sara Delghandi1, Kazuhiro Sonomura3, Tomonori Yaguchi1,2, Tasuku Honjo1, Kenji Chamoto1,2 (1.Division of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto 606-8501, Japan, 2.Department of Immuno-Oncology PDT, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto 606-8501, Japan, 3.Life Science Research Center, Technology Research Laboratory, Shimadzu Corporation, Kyoto, Japan)
[WS22-04-P]IFN-γ Modulation of Type 2 Immune Response enhances T cell Anti-tumor Immunity
○Tzu-Hsuan Chang1,2, Francesca Alfei3, Stefania Vilbois1,2, Yingxi Xu1,2,4,5, Ping-Chih Ho1,2 (1.Department of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland., 2.Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Lausanne, Switzerland, 3.Amal Therapeutics, Av. de la Roseraie 64, Genève, Switzerland, 4.National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, 5.Tianjin Institutes of Health Science, Tianjin, China)
[WS22-05-P]PIGR mediates susceptibility of tumor cells to cytotoxicity of CD8+ T cells
○Chenxu Jiang1, Kiyoshi Yasui1, Situo Deng1, Mitsuhiro Yoneda1, Yasuhiro Nagata2, Hiroaki Ikeda1 (1.Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2.Leading Medical Research Core Unit, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan)
[WS22-06-P]Depletion of CD4+ T cells suppressed tumor growth in a murine model of lung cancer with pulmonary fibrosis through enhancing anti-tumor effects of CD8+ T cells
○Takehiro Sakabe, Masahiro Kitabatake, Noriko Ouji-Sageshima, Ryutaro Furukawa, Tatsuki Nishioka, Toshihiro Ito (Department of Immunology, Nara Medical University)
[WS22-07-P]The role of histone demethylase Phf2 in T cell immune responses and effect of Phf2 deficiency on antitumor activity
○Yuzuki Tano1, Yuya Arakawa2, Yuri Tsuchiya3, Rina Matsuda1, Honoka Myahara1, Ayumi Sumizaki1, Masaki Yasukawa1,3, Takeshi Yamada1,3 (1.Department of Medical Technology, Ehime Prefectural University of Health Sciences, 2.Department of Clinical Laboratory and Biomedical Sciences, Osaka University Graduate School of Medicine, 3.Department of Medical Technology, Ehime Prefectural University of Health Sciences Graduate School of Medicine)
[WS22-08-O/P]T cell exhaustion steps according to mitochondrial status and the analysis of their glycolytic function
○Koji Kitaoka1, Yasuharu Haku1, Tomonori Yaguchi1,2, Tasuku Honjo1, Kenji Chamoto1,2 (1.Center for Cancer Immunotherapy and Immunobiology Graduate School of Medicine Kyoto University, 2.Department of Immuno-Oncology PDT, Graduate School of Medicine Kyoto University)
[WS22-09-P]Possible involvement of miR-31 in T cell exhaustion mediated by a T-box transcription factor, Eomesodermin
○Ritsuki Tanabe, Ryuichi Nagashima, Hiroaki Takimoto, Koji Eshima (Division of Immunology, Kitasato University Graduate School of Science)
[WS22-10-O/P]A novel pro-tumourigenic mechanism of Ex-Regs in cancer
○Qiao Gou1, Hiroyuki Takaba1, Daizo Koinuma2, Kohei Miyazono2,3, Hiroshi Takayanagi1 (1.Department of Immunology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, 2.Department of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, 3.Department of Applied Pathology, Graduate School of Medicine, The University of Tokyo)
[WS22-11-P]Prostaglandin E2 – EP2/EP4 signaling induces an active phenotype of regulatory T cells characteristic in tumor microenvironment
○Ryuma Matsuura, Shuh Narumiya (Department of Drug Discovery Medicine, Kyoto University Graduate School of Medicine)
[WS22-12-P]A subset of tumor associated macrophages secrete TiHF1 and promote tumor growth through Th1-Treg polarization
○Ayumi Kuratani1, Masahiro Yamamoto1,2,3 (1.Department of Immunoparasitology, RIMD, Osaka University, 2.Laboratory of Immunoparasitology, IFReC, Osaka University, 3.CIDER, Osaka University)
[WS22-13-O/P]Establishment of monoclonal antibodies derived from tumor-infiltrating B cells for cancer therapeutic application.
○Tsubasa Kobayashi1, Toshihiro Suzuki2, Tetsuya Nakatsura2, Daisuke Kitamura1 (1.Research Institute for Biomedical Sciences, Tokyo University of Science, 2.Division of Cancer Immunotherapy, EPOC, National Cancer Center)
[WS22-14-P]Withdrawn
[WS22-15-O/P]Impacts of tumor-derived DCs on the thymus function
○Yangsong Wang, Ichita HASEGAWA, Yukihiro ENDO, Ryo NASU, Motoko KIMURA (Chiba University)
[WS22-16-P]Clec4A4/CLEC4A acts as a negative immune checkpoint regulator to suppress anti-tumor immunity
○Tomofumi Uto, Tomohiro Fukaya, Shuya Mitoma, Moe Tominaga, Katsuaki Sato (Division of Immunology, Department of Infectious Diseases, Faculty of Medicine, University of Miyazaki)
[WS22-17-P]Glioblastoma stem-like cells evade immune response via CD47 and PD-L1 expression
○Masaki Yoshioka1, Syunsei Noguchi2, Masayoshi Kobayashi1,3, Shinichiro Motohashi3, Yasuo Iwadate1,4 (1.Department of Neurological Surgery, Graduate School of Medicine, Chiba University, 2.School of Medicine, Chiba University, 3.Department of Medical Immunology, Graduate School of Medicine, Chiba University, 4.Eastern Chiba Medical Center)
[WS22-18-P]Extracellular acidity in tumor tissue upregulates PD-L1 expression on tumor cells via proton-sensing G protein-coupled receptors
○Daichi Mori1,2,3, Takahiro Tsujikawa1, Gaku Omura1, Osam Mazda2, Shigeru Hirano1, Tsunao Kishida2 (1.Department of Otolaryngology-Head & Neck Surgery, Kyoto Prefectural University of Medicine, 2.Department of Immunology, Kyoto Prefectural University of Medicine, 3.Department of Otolaryngology-Head & Neck Surgery, Red Cross Society Kyoto Daiichi Hospital)
[WS22-19-P]Histone Deacetylation in the Regulation of MHC Class I Gene Expression
○Alaa Ahmad1, An Ning1, Yusuke Kasuga1, Ryota Ouda1, Xin Sun1, Tsutomu Tanaka1,3, Koichi S Kobayashi1,2,3 (1.Hokkaido University, Graduate School of Medicine, Department of Immunology, 2.Texas A&M University, Department of Microbial Pathogenesis and Immunology, 3.Hokkaido University Institute for Vaccine Research and Development)
[WS22-20-P]Epithelial cells induce cell death in precancerous cells via the MHC-I interaction
○Shiyu Ayukawa, Nagisa Kamoshita, Takeshi Maruyama (Tokyo University of Pharmacy and Life Sciences)
[WS22-21-P]Binding affinity and specificity analysis of anti-HLA-G antibodies for anti-tumor immune activation
○Yuhi Kuriki1, Yoji Mori1, Sakie Shimokakimoto1, Kazuma Hikichi1, Naruki Akaiwa1, Hisashi Arase2, Atsushi Furukawa1,3, Naoyoshi Maeda1,4, Kimiko Kuroki1, Katsumi Maenaka1,5,6,7 (1.Faculty of Pharmaceutical Sciences, Hokkaido University, 2.Immunology Frontier Research Center, Osaka University, 3.Faculty of Pharmaceutical Sciences Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 4.Faculty of Pharmacy, Health Sciences University of Hokkaido, 5.International Institute for Zoonosis Control, Hokkaido University, 6.Creative Research Institution, Institute for Vaccine Research and Development, Hokkaido University, 7.Faculty of Pharmaceutical Sciences, Kyusyu University)
[WS22-22-P]Analysis of candidate antibodies inhibiting immune checkpoint receptor function for antitumor immune activation
○Tomokatsu Nishiuchi1, Ryota Koseki1, Naruki Akaiwa1, Hiroshi Ito2, Koji Nakamura2, Kimiko Kuroki1, Katsumi Maenaka1,3,4,5,6 (1.Hokkaido University Graduate School of Pharmaceutical Sciences Laboratory of Biomolecular Science, 2.Chiom BioScience Inc., 3.Hokkaido University center for Research and Education on Drug Dicovery, 4.Hokkaido University International Institute for Zoonosis Control, 5.Hokkaido University Creative Research Institution for Vaccine Research and Development, 6.Kyusyu University Graduate School of Pharmaceutical Sciences)
[WS22-23-P]The Analysis of cell surface expression of novel immune checkpoint molecule HLA-F on colorectal cancer cells
○Noriko Ouji-Sageshima, Shinomiya Reina, Masahiro Kitabatake, Ryutaro Furukawa, Atsushi Hara, Ito Tishihiro (Department of Immunology, Nara Medical University)
[WS22-24-O/P]Deletion of the endoribonuclease Regnase-1 unleashes NK cell anti-tumor activity via OCT2-dependent transcription of Ifng
○Yasuharu Nagahama1,2, Shizuo Akira1,3,4 (1.Laboratory of Host Defense, WPI Immunology Frontier Research Center, Osaka University, 2.Host Defense Laboratory, Immunology Unit, Osaka Research Center for Drug Discovery, Otsuka Pharmaceutical Co., Ltd., 3.Center for Advanced Modalities and Drug Delivery System, Osaka University, 4.Department of Host Defense, Research Institute for Microbial Diseases, Osaka University)
[WS22-25-P]Deficiency of nuclear receptor Nr4a3 alleviates colitis-associated cancer in mice
○Niya Yamashita1, Natsuki Minamikawa1, Naoto Ito1, Mayuka Katagiri1, Kazuki Nagata1, Akihiko Yoshimura2, Chiharu Nishiyama1 (1.Department of Biological Science and Technology, Faculty of Advanced Engineering, Tokyo University of Science., 2.Research Institute for Biomedical Sciences, Tokyo University of Science.)
[WS22-26-P]Effect of myeloid-specific Ezh2 deficiency in tumor formation in hepatocellular carcinoma mouse model
○Benjawan Saechue1, Kittin Weerasopon2,3, Atsadang Boonmee4, Haruhiko Koseki5, Tanapat Palaga3,6 (1.Faculty of Veterinary Science, Mahasarakham University, Mahasarakham, Thailand, 2.Graduate Program in Biotechnology, Faculty of Science, Chulalongkorn University, Bangkok, Thailand, 3.Center of Excellence in Immunology and Immune-mediated Diseases, Chulalongkorn University, Bangkok, Thailand, 4.Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand, 5.Laboratory for Developmental Genetics, Center for Integrative Medical Sciences, RIKEN, Japan, 6.Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok, Thailand)
[WS22-27-O/P]Fibroblastic reticular cell-derived CXCL12 controls immunosuppression in tumor-draining lymph nodes
○Yasuhiro Kanda1, Madoka Ozawa1, Takashi Nagasawa2, Tomoya Katakai1 (1.Department of Immunology, Niigata University Graduate School of Medical and Dental Sciences, 2.Laboratory of Stem Cell Biology & Developmental Immunology, Graduate School of Frontier Biosciences, Osaka University)
[WS22-28-O/P]LPS promotes mast cells induced fibrosis in cancer tissue by increasing CXCL8 and CCL19 expression
○Xiangmei Zhang1, Jidong Zhao2, Baoen Shan1 (1.Hebei Provincial Cancer Institute, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China, 2.Department of Thoracic Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China)